ReviewPharmacoEconomics2016
A Methodological Review of US Budget-Impact Models for New Drugs.
Review in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review.Frontiers in public health · 2021Pooled it
- Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.PharmacoEconomics · 2018Pooled it
- Accuracy of Budget Impact Projections in Bulgarian Health Technology Assessment: A Five-Year Validation Study (2020-2025).Healthcare (Basel, Switzerland) · 2025Article
- Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective.Journal of managed care & specialty pharmacy · 2025Article
- Methods and Practical Considerations for Conducting Budget Impact Analysis for Non-Pharmaceutical Interventions.Applied health economics and health policy · 2025Review
- Budget Impact Analysis of Implementing Antenatal Care Recommendations for Positive Pregnancy Outcomes at Public Primary Facilities in Tanzania.Applied health economics and health policy · 2025Article
- Budget Impact and Cost-Effectiveness of Intravenous Meloxicam to Treat Moderate-Severe Postoperative Pain.Advances in therapy · 2022Article
- Economic impact of generic antiretrovirals in France for HIV patients' care: a simulation between 2019 and 2023.BMC health services research · 2022Article
- Prostate cancer follow-up costs in Germany from 2000 to 2015.Journal of cancer survivorship : research and practice · 2022Article
- Payer perceptions on the use of economic models in oncology decision making.Journal of managed care & specialty pharmacy · 2021Article
- Adoption of RTS, S malaria vaccine for children younger than 5 years in Rwanda: A budget impact analysis.Exploratory research in clinical and social pharmacy · 2021Article
- The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil.Applied health economics and health policy · 2021Article
- Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions.PharmacoEconomics - open · 2021Article
- Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review.Frontiers in pharmacology · 2021Review
- Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria.Frontiers in pharmacology · 2021Article
- A systematic review of the budget impact analyses for antitumor drugs of lung cancer.Cost effectiveness and resource allocation : C/E · 2020Review
- Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.Journal of managed care & specialty pharmacy · 2020Article
- Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective.Human vaccines & immunotherapeutics · 2020Article
- A budget impact analysis of a magnetic sphincter augmentation device for the treatment of medication-refractory mechanical gastroesophageal reflux disease: a United States payer perspective.Surgical endoscopy · 2020Article
- Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.Journal of managed care & specialty pharmacy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A budget-impact analysis is required by many jurisdictions when adding a new drug to the formulary. However, previous reviews have indicated that adherence to methodological guidelines is variable. In this methodological review, we assess the extent to which US budget-impact analyses for new drugs use recommended practices. We describe recommended practice for seven key elements in the design of a budget-impact analysis. Targeted literature searches for US studies reporting estimates of the budget impact of a new drug were performed and we prepared a summary of how each study addressed the seven key elements. The primary finding from this review is that recommended practice is not followed in many budget-impact analyses. For example, we found that growth in the treated population size and/or changes in disease-related costs expected during the model time horizon for more effective treatments was not included in several analyses for chronic conditions. In addition, all drug-related costs were not captured in the majority of the models. Finally, for most studies, one-way sensitivity and scenario analyses were very limited, and the ranges used in one-way sensitivity analyses were frequently arbitrary percentages rather than being data driven. The conclusions from our review are that changes in population size, disease severity mix, and/or disease-related costs should be properly accounted for to avoid over- or underestimating the budget impact. Since each budget holder might have different perspectives and different values for many of the input parameters, it is also critical for published budget-impact analyses to include extensive sensitivity and scenario analyses based on realistic input values.
Indexed as
Identifiers
27334107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.